In these studies, we found that Evo inhibits insulin-stimulated mammalian target of rapamycin (mTOR)-ribosomal S6 protein kinase (S6K) activation in 3T3-L1 adipocytes and WAT, a mechanism which contributes to the improvement of obesity and insulin resistance in obese models. Here, RPS6KB1 is linked to obesity disorder.